Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06963281 · ClinicalTrials.gov registry record · Phase 1
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 285
- Enrollment target
- 9
- Study locations
NCT06963281 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Innovent Biopharmaceutical Technology (Hangzhou) Co.. The registered enrollment target is 285 participants, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target. The trial reports 9 study locations across 8 states.
The verdict
NCT06963281, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 285 participants
- Enrollment target
- 9
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.
Conditions Studied
Interventions
- DRUG IBI3020
Study Locations (9)
Texas
- NEXT Houston - Houston
- NEXT Dallas - Irving
Arizona
- Mayo Clinic - Arizona - Pheonix
Florida
- Mayo Clinic - Florida - Jacksonville
Minnesota
- Mayo Clinic - Rochester - Rochester
New York
- Montefiore Cancer Center - New York
Guangdong
- The sixth affiliated hospital, Sun Yat-sen University - Guangzhou
Shandong
- Shandong Cancer Hospital - Jinan
Shanxi
- Shanxi Cancer Hospital - Taiyuan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06963281
The ClinicalTrials.gov registry entry for NCT06963281 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target. The listed sponsor is Innovent Biopharmaceutical Technology (Hangzhou) Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which IBI3020 is the first listed.
NCT06963281 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Texas, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06963281 about?
NCT06963281 is a clinical study titled "Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors". The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.
What is the current status of trial NCT06963281?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 285 participants. The study started on 2025-04-29. Estimated completion is 2028-03-31.
What conditions does trial NCT06963281 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT06963281?
The interventions under investigation include: IBI3020 (DRUG).
Who is sponsoring clinical trial NCT06963281?
This trial is sponsored by Innovent Biopharmaceutical Technology (Hangzhou) Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06963281 being conducted?
This trial has 9 study locations across Arizona, Florida, Minnesota, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.